Cantor Recommends Isis Pharma And Star Bulk Carriers (ISIS, SBLK)
Isis Pharmaceuticals Inc. (NYSE: ISIS) has a healthy pipeline and a solid balance sheet. Equity research firm Cantor has given the pharma company a “Buy” rating. Isis (ISIS) is making good progress on its programs and its proprietary and collaborative candidates are rapidly moving into Phase II and III clinical studies. Such progress indicates safety and efficacy and thus validates the long-term potential of this drug class in oncology. Isis’s 12-months price target has been set at $28.
Star Bulk Carriers (NASDAQ: SBLK) is well positioned to expand due to its strong balance sheet. Cantor has adjusted its 2010 estimates on account of the drydocking schedule. Star Bulk (SBLK) is expected to report EPS of 2 cents and its EBITDA estimates have been raised from $57 million to $58 million. Cantor has reiterated its “Buy” recommendation for the stock with a price target of $4.
